Investor Relations & Capital Introduction Services in Switzerland

Across most developed venture markets, 2025 was a year in which early-stage capital retreated. Switzerland went the other way. Seed and Series A investment reached a record CHF 1.116 billion, an increase of roughly 73% year on year and the largest jump in Series A funding since 2018.

Total venture capital invested in Swiss startups reached approximately CHF 2.95 billion across 354 financing rounds, up around 23.9% on 2024. That was the first annual increase since 2022 and ended a two-year contraction. Deal count remained broadly stable while capital grew, which is a healthier combination than the concentration pattern visible in most comparable markets.

Global Capital Network provides investor relations and capital introduction services for companies raising in Switzerland, and for allocators seeking structured access to Swiss dealflow. In a market where early-stage capital is genuinely available rather than nominally so, the constraint shifts from finding money to finding the right investor for a technically complex business.

Capital Raising & Investor Introductions in Switzerland

The early-stage surge is the defining feature of the Swiss market and it deserves proper attention. Investment into young and very young companies rose from approximately CHF 864 million in 2024 to more than CHF 1.1 billion in 2025. Seed funding alone grew around 23.8%, the second-highest figure on record. For a founder at the beginning of a company's life, Switzerland is currently one of the more receptive markets in Europe.

Artificial intelligence became the dominant cross-sector theme rather than a category of its own. Some 163 AI-related funding rounds closed during 2025, up from 112 the previous year, representing roughly 32% of all Swiss deals and approximately CHF 1.1 billion of investment volume. That is a 206% increase in AI investment volume year on year, and it ran across legal technology, asset management, robotics, and semiconductor cooling rather than concentrating in a single application area.

Information and communications technology recovered sharply, roughly tripling to around CHF 773.6 million after a difficult 2024. Cleantech attracted approximately CHF 386 million, though concentration should be noted, with about a third of that going to one company. Biotechnology continued to anchor the market, recording a record first half at approximately CHF 705 million even as deal count declined, reflecting a shift toward larger rounds in drug development.

The exit picture also improved. After a year with no initial public offerings, two Swiss startups listed in 2025. Two acquisitions exceeded CHF 1 billion in transaction value and seven exceeded CHF 100 million, while the overall number of companies sold to corporates or financial buyers held stable.

GCN supports Swiss companies across seed, growth and later stages, with particular attention to matching technically complex businesses with investors who can actually assess them.

Pitch Deck Design & Fundraising Preparation

Switzerland produces an unusually high proportion of companies emerging from research institutions, and that shapes what preparation must accomplish. A generalist investor assessing a spinout needs the science translated without being simplified into meaninglessness, which is a harder writing problem than most founders anticipate.

GCN works with founders on precisely that translation. Whether the technical claim is stated in terms an investor can evaluate. Whether the development timeline and the capital required to reach commercial revenue are set out honestly. Whether intellectual property position and any institutional arrangement are clear rather than glossed over.

For life sciences companies, preparation extends to clinical pathway and regulatory strategy. Switzerland's biotech sector shifted toward larger rounds concentrated in fewer companies during 2025, which means the standard of evidence at each stage has risen even as total capital grew.

Swiss companies also face a market-size question that founders in larger economies do not. The domestic market cannot support a venture-scale outcome on its own, so investors will assess international expansion capability early. A credible European or global go-to-market plan is not optional here.

Investor Events, Dinners & Networking in Switzerland

Swiss venture activity concentrates around Zurich, Lausanne, Geneva and Basel, each with a distinct character shaped by the research institution or industry closest to it. The distances are short, which makes multi-city engagement practical in a way it is not in most markets.

GCN convenes private investor dinners and closed sessions matched by sector and stage, with mandates verified in advance. Given how technically specialised Swiss dealflow is, sector matching carries unusual weight: a biotech founder and a robotics founder need entirely different rooms.

Our programming addresses where Swiss capital is concentrated: biotechnology and life sciences, deep technology and robotics, applied artificial intelligence, information and communications technology, cleantech, and financial technology. Sessions are scheduled around the established Swiss and European calendar so that visiting allocators can participate without arranging separate travel.

Investor Webinars & Digital Capital Access

Switzerland attracts substantial international investor attention relative to its size, and reaching those allocators requires formats that do not depend on physical presence.

GCN runs online investor sessions connecting Swiss founders with allocators across Europe, North America and Asia. These are structured for assessment rather than exposure, with short presentations, protected question time, and follow-up routed only to investors who signal genuine interest.

Hybrid formats pair a Zurich, Lausanne or Basel gathering with remote attendance, extending reach to London, Munich, Boston and San Francisco. For life sciences companies in particular, connecting with specialist investors in established biotech clusters matters more than general reach.

Services for Investors in Switzerland

For allocators, Switzerland offers a combination that is genuinely rare: technical depth from world-class research institutions, a stable and predictable legal environment, strong intellectual property protection, and a venture market small enough that meaningful coverage is achievable.

On a per capita basis, Switzerland ranks second in Europe for venture capital investment, behind only Finland, and ahead of the United Kingdom, Sweden, France and Germany. That efficiency reflects a pipeline that converts research into fundable companies at an unusual rate.

The 2025 data also suggests durability rather than a temporary bounce. Overall growth of nearly 24%, stable deal flow rather than concentration into a handful of transactions, and record early-stage activity together point to a market rebuilding from the bottom rather than being propped up at the top.

GCN provides curated dealflow filtered against stated criteria rather than general distribution, and remains involved through diligence rather than stepping back at introduction.

GCN Deal Flow Platform & Investor Matching

Our platform organises Swiss opportunities by sector, stage, geography and thesis. Given the technical specialisation of Swiss dealflow, sector filtering carries more signal here than almost anywhere: an investor building life sciences exposure and one building robotics exposure are looking at genuinely different ecosystems within the same small country.

Matching operates on cheque size, stage preference, sector mandate and geographic scope, with attention to whether an investor has the domain capability to assess a given company.

Why Switzerland Is Attractive for Investors

Early-stage capital is expanding, not contracting. Seed and Series A investment reached a record CHF 1.116 billion in 2025, up roughly 73% year on year, running counter to the pattern in most developed venture markets.

The recovery is broad rather than concentrated. Total investment grew approximately 23.9% to CHF 2.95 billion while deal count held broadly stable at 354 rounds, indicating capital reaching more companies rather than fewer.

Capital efficiency is structural. Switzerland ranks second in Europe for venture capital investment per capita, ahead of the United Kingdom, Sweden, France and Germany, reflecting a research base that converts into fundable companies at an exceptional rate.

Exit routes reopened in 2025. Two initial public offerings followed a year with none, alongside two acquisitions above CHF 1 billion and seven above CHF 100 million.

Partner with Global Capital Network in Switzerland

For founders raising in Switzerland, GCN provides investor relations infrastructure connecting Swiss companies with domestic and international capital. Our approach is relationship-led, and we judge our work by whether an introduction still matters two funding rounds later.

For investors seeking Swiss exposure, we deliver curated dealflow, diligence support and relationship facilitation across the sectors where Swiss companies are strongest. Whether you allocate as a fund, a family office, or a strategic acquirer, our role is to shorten the distance between your mandate and the companies that match it.

To discuss your objectives in Switzerland, whether you are based in Zurich, Lausanne, Geneva, Basel, or engaging from international markets, our team is available to talk through how we can help.